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LeukemiaMonocyte/macrophages play an important role in orchestrating the immune response. The present review
refers to C/EBPβ, which is a key transcription factor regulating monocytic gene expression. Following a gen-
eral introduction to C/EBPβ, this article focuses on activators and regulators of the C/EBPβ system in mono-
cytic cells, including differentiating agents, cytokines, and bacterial products as well as associated signaling
pathways. Furthermore, C/EBPβ target genes in monocytic cells are summarized and resulting functions
are described, including regulation of proliferation and differentiation as well as orchestration of processes
of mainly the innate immune response. In addition, a variety of disease stages are described in which a dys-
regulation of the C/EBPβ system may be involved. A detailed knowledge of the C/EBPβ system in monocytic
cells may help to further understand the difference between inﬂammatory and malignant proliferation as
well as additional regulatory facets of innate immunity.
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Monocytes are bone marrow-derived mononuclear cells giving rise
to macrophages and dendritic cells (DC) with which they are forming
1288 R. Huber et al. / Cellular Signalling 24 (2012) 1287–1296the mononuclear phagocyte system [1,2]. Thus, they are part of the cel-
lular arm of the innate immune system representing an important
subgroup of the leukocytes [1]. Moreover, by covering antigen presen-
tation,monocytic cells connect innate and adaptive immunity. Originat-
ing from hematopoietic stem cells, monocytes arise in the interplay of
proliferation and differentiation. The monocytic development in the
bone marrow comprises several premonocytic stages including multi-
potent progenitors (MPP;without self-renewal capacity), commonmy-
eloid progenitors (CMP; the source for all myeloid cells), and the
granulocyte/macrophage progenitor (GMP) [3]. The further differen-
tiated monocyte/macrophage and dendritic cell progenitor (MDP)
has lost its granulocyte-forming potential but provides the basis for
monocyte development [1]. Differentiated monocytes translocate
to the blood where they are circulating in an inactive steady state,
patrolling on the endothelial cells [1,4]. In humans, three monocytic
subsets were identiﬁed: classical monocytes (CD14++CD16−), in-
termediate monocytes (CD14++CD16+), and non-classical mono-
cytes (CD14+CD16++) [5,6]. Following emigration from the blood
vessels into the respective tissue, monocytes may differentiate
under physiological conditions into resident macrophages and DC
(e.g. forming alveolar macrophages in the lung, Kupffer cells in
the liver, white-pulp and metallophilic macrophages in the spleen,
or microglia in the central nervous system) which are involved in
tissue homeostasis [1,4,7]. When invading inﬂamed or damaged
tissue, monocytes conduct initial proinﬂammatory and antimicro-
bial processes [8]. Subsequently, these monocytes may either efﬁ-
ciently differentiate within hours into inﬂammatory macrophages
or DC [1,4] or into alternatively activated macrophages supporting
tissue remodeling, wound repair, and immunomodulation [1]. Lo-
cally, monocyte/macrophages potentiate the immune response by
cytokine and chemokine production, phagocytosis, and/or antigen
presentation [4,9]. Finally, degenerated or transformed monocytic
cells contribute to the development and/or progression of disease
states such as leukemia [3], sepsis and inﬂammatory diseases [10] as
well as persistence of microbial infections [6,8]. C/EBPβ represents
one of the key transcription factors involved in the regulation of mono-
cytic gene expression [11,12]. A variety of monocytic key features and
functions such as proliferation/differentiation as well as orchestration
of the immune response and phagocytosis, but also certain pathophys-
iological events such as acutemyeloid leukemia (AML) or inﬂammatory
processes, e.g. sepsis and bacterial/viral infections, appear to be (dys)
regulated or modulated by C/EBPβ [11,12].
2. The transcription factor C/EBPβ
2.1. General aspects
CCAAT/enhancer-binding protein β (C/EBPβ) is a member of the C/
EBP family of transcription factors currently consisting of 6 members:
C/EBPα, C/EBPβ (also known as NF-IL6, IL6-DBP, CRP2, NF-M, AGP/
EBP, ApC/EBP, or TCF5), C/EBPγ, C/EBPδ, C/EBPε, and C/EBPξ (for review
see [11,13,14]). The founding member of the family, C/EBPα, was ﬁrst
described in 1986 as a protein puriﬁed from rat liver binding to double
stranded viral DNA sequences exhibiting CCAAT-motifs [15,16] and fur-
ther studies led to the further characterization of C/EBPα and the sub-
sequently discovered family members [11,14,17]. C/EBPβ was ﬁrst
described in 1990 as a basic leucine zipper (bZIP)-structured factor
binding to the interleukin 1 (IL-1)-responsive element in the IL-6 pro-
moter (thus initially denoted as nuclear factor for IL-6 (NF-IL6)) and
characterized by high C-terminal homology to C/EBPα [18].
In addition to other tissues (liver, lung, spleen, kidney, etc.), C/
EBPβ is highly expressed in myelomonocytic cells and macrophages
[19–22]. A variety of extracellular signals such as differentiation- or
proliferation-inducing agents, hormones, cytokines and inﬂammatory
substances as well as bacterial and other microbial products can act as
activators or inhibitors of C/EBPβ via distinct signal transductionpathways [11], (see Section 3). The expression and/or activation of C/
EBPβ is regulated in a complexway, e.g. by transcriptionalmechanisms,
mammalian target of rapamycin (mTOR)-mediated alternative transla-
tion, post-translational modiﬁcations, and protein–protein interactions,
and have been extensively reviewed elsewhere [13,23,24]. Following
activation, several classes of genes are induced or repressed by C/
EBPβ: cytokines, chemokines, their respective receptors, and other
proinﬂammatory genes, proproliferative or differentiation-related
markers as well as metabolic enzymes [11]. Consequently, relevant cel-
lular functions such as proliferation [21,22], differentiation [20,22,25],
metabolic regulation [26,27], and orchestration of the immune response
(e.g. by cytokine production or phagocytosis [28–30]) are affected by C/
EBPβ. Moreover, due to its cellular relevance C/EBPβmay be involved in
the pathogenesis of common diseases, e.g. cancer, hyper-/hypo-inﬂam-
mation, and bacterial/viral infections [11,12].2.2. Expression of C/EBPβ
The C/EBPβ promoter contains a TATA box and binding sites for sev-
eral transcription factors regulating C/EBPβmRNA expression including
C/EBPβ itself [31–33], signal transducer and activator of transcription 3
(STAT3) [34], speciﬁcity protein 1 (Sp1) [35], members of the cAMP-
responsive element binding protein (CREB)/activating transcription
factor (ATF) family [35,36], early growth response 2 (EGR2) [37], Fos-
related antigen 2 (Fra-2) [38], sterol-regulatory element-binding pro-
tein 1c (SREBP1c) [39], myoblastosis transcription factor (Myb) [40],
and retinoic acid receptor α (RARA) [41]. The human gene coding for
C/EBPβ (CEBPB, chromosomal localization: 20q13.13) is encoded by a
single exon [42,43]. The yielding single mRNA (gene bank accession
number NM_005194.2) spans a total of 1837 bases (overall G/C con-
tent: 66%), including 195 bases 5′UTR (G/C content: 77%), 1038 bases
coding for C/EBPβ protein (incl. stop codon, G/C content: 74%), and
604 bases 3′UTR (G/C content: 50%).
The C/EBPβmRNA half-life is approx. 40–60 min [44,45] but may be
altered by mRNA stability-modifying proteins, especially HuR which
binds the 3′UTR of the C/EBPβ mRNA and prolongs its half-life up to
110 min [45]. In addition, binding of HuR to the C/EBPβmRNAmay re-
sult in nuclear retention of themRNA including the limitation of C/EBPβ
translation in the cytosol [46]. Recently, it has been shown that C/EBPβ
mRNA-bound HuR also plays a key role in the sequestration of C/EBPβ
proteins from kinase-containing perinuclear cytosolic compartments
thus preventing C/EBPβ proteins from activation [47].
Translation of the CEBPB mRNA results in the synthesis of three C/
EBPβ isoforms: liver-enriched activating protein* (LAP* or C/EBPβ1),
liver-enriched activating protein (LAP or C/EBPβ2), and liver-enriched
inhibitory protein (LIP or C/EBPβ3) [13,48]. Human LAP* is a 44 kDa
protein consisting of 345 amino acids (murine: 38 kDa/296 aa) and
LAP is only slightly shorter (human: 42 kDa, 322 aa; murine: 34 kDa/
275 aa). Both proteins exhibit a half-life of about 2 h. In contrast, LIP
represents a markedly truncated C/EBPβ version (human: 20 kDa, 147
aa; murine: 20 kDa, 145 aa) with a half-life of approx. 8.5 h.
The formation of the different isoforms ismainly based on alternative
translation affecting three different in-frame initiation codons at the po-
sitions +196 (for LAP*), +265 (for LAP), and +790 (for LIP) of the
human mRNA [42,43]. This procedure depends on (i) weak Kozak con-
sensus sequences around LAP* and LAP initiation codons in combination
with an optimal Kozak context for LIP [42,43], (ii) an ex-frame upstream
open reading frame (uORF; position+225)which is essential for LIP ex-
pression [42,43], and (iii) themodulation of the translationmachinery by
translation initiation factors (especially eIF-2α and eIF-4E) [42] or
CUGBP1 [49] combined with leaky scanning of the ribosome [50,51]. In
addition to alternative translation, the generation of LIP through directed
proteolytic cleavage of the larger C/EBPβ isoforms has been discussed
[52], presumably effected by μ-calpain [53] or the proteasome [54]. How-
ever, since protein isolation is sometimes accompanied by proteolytic
1289R. Huber et al. / Cellular Signalling 24 (2012) 1287–1296cleavage of full-length C/EBPβ in vitro [55], the in vivo relevance of this
phenomenon has not been fully elucidated yet.
2.3. Structure and function of C/EBPβ
The C/EBPβ protein structure is characterized by an N-terminal sec-
tionmainly harboring up to three transactivation domains (TAD1-3; ab-
sent in LIP) and two regulatory domains (RD1 and 2 in LAP* and LAP; in
LIP the RD2 region is complete while RD1 exists in a truncated form)
[11,56]. C/EBPβ and the other C/EBP proteins share a highly conserved
C-terminus (>90% sequence identity)which contains a basic DNAbind-
ing domain adjacent to a leucine zipper-type dimerization domain (for
review see [11,13,14,17,24]). Following dimerization, the DNA binding
domains mediate binding activity to their corresponding DNA binding
sequences (ideal binding sequence: ATTGCGCAAT, a variant of the gen-
eral C/EBP consensus sequence A/GTTGCGC/TAAC/T) [57] as well as pro-
tein homo- and/or heterodimerization [24].
Various post-translational modiﬁcations and events including phos-
phorylation, acetylation, methylation, sumoylation, and proteolysis
strictly regulate dimerization, cellular localization, DNA binding, and
the transactivation activity of C/EBPβ [11,13,24,58]. Furthermore, C/
EBPβ transactivation capacity is based on the presence (C/EBPβ-LAP*
and -LAP) or absence (C/EBPβ-LIP) of intrinsic transactivation potential,
the structure of the respective transactivating isoform (C/EBPβ-LAP or
C/EBPβ-LAP*), the relative amount of actually present isoforms (LAP/
LIP ratio), as well as on the appropriate dimerization/interaction part-
ners [11,13,24]. C/EBPβ-dependent target gene activation further de-
pends on the composition of target gene promoters as well as on the
respective cell-, tissue-, and species-speciﬁc conditions [11,13,24]. In
consequence, LAP*, LAP, and LIP exhibit distinct functions.
In general, LAP* is a less potent activator of gene transcription than
LAP with respect to pure transactivation activity [56], presumably
based on the formation of an additional disulﬁde bond [59]. However,
its extended N-terminus appears to mediate the recruitment of the
‘switch/sucrose nonfermentable’ (SWI/SNF) nucleosome remodeling
complex and this interactionmay not only enable the activation of usu-
ally silenced genes but also facilitate the interaction of LAP* with the
myeloid-speciﬁc transcription factor c-Myb [60]. Therefore, in the re-
spective context, the cooperation with other transcription factors and
regulators renders LAP* a more effective (co)regulator of myeloid
genes than LAP [60]. In contrast, LIP is generally regarded as a dominant
inhibitor of transcriptionally active C/EBPs including LAP* and LAP [61].
In addition to dimerization with proteins of the same family, C/EBPβ
is also able to interact/cooperate with other proteins thus expanding the
accessible DNA binding motifs and modifying C/EBP protein functions
and speciﬁcities like initiation of target gene transcription [24]. Known
protein interaction partners of C/EBPβ are other bZIP-structured tran-
scription factors, e.g.members of the Jun/Fos [62] and the CREB/ATF fam-
ilies [63]. In addition, C/EBPβmay interact with non-bZIP proteins such
as nuclear factor-κB (NF-κB) subunits p65 [29] and p50 [64], glucocorti-
coid receptor [65], retinoblastoma protein (Rb), E2F [66,67], c-Myb [60],
SWI/SNF, protein arginine N-methyltransferase-4 (PRMT4)/coactivator-
associated arginine methyltransferase 1 (CARM1) [68], p300/CREB-
binding protein (CBP) [69], the mediator complex [51], PU.1 [25,70],
death-associated protein 6 (Daxx) [71], C-repeat binding factors (CBF),
and runt-related transcription factor (Runx) proteins [72]. Moreover,
by adopting the function of a binding partner for other transcription fac-
tors (especially NF-κB, glucocorticoid receptor, and Runx2), LIP may also
contribute to gene expression via accessing certain promoters [13].
3. Activators and modulators of C/EBPβ in monocytic cells and
associated signaling pathways
In myelomonocytic cells and monocyte/macrophages, C/EBPβ is
regulated by a variety of differentiation- and proliferation-inducingagents, cytokines and inﬂammatory substances as well as bacterial
and other microbial products (Fig. 1).
3.1. Differentiation-inducing agents
In human promyelocytic leukemia HL60 cells stimulated with 12-O-
tetradecanoylphorbol-13-acetate (TPA; also known as phorbol 12-
myristate 13-acetate, PMA), the expression of C/EBPβmRNA is strongly
induced [73]. Avian leukemia virus E26-infected multipotential stem
cells from chicken which were differentiated towards the myelomono-
cytic lineage using PMA exhibited increased levels of C/EBPβ protein
[20]. In addition, the combination of PMA and lipopolysaccharide
(LPS) enhanced C/EBPβ promoter activity and transcriptional initiation
in a CREB/ATF- and Sp1-dependent manner resulting in increased ex-
pression levels of C/EBPβ mRNA [35] and the larger C/EBPβ proteins
in histiocytic leukemia U937 cells [73]. Moreover, the stimulation of
chicken macrophages with TPA caused the translocation of C/EBPβ to
the nucleus [20]. In human premonocytic THP-1 cells, a PMA-induced
increase in all C/EBPβ isoforms occurs together with an increase in the
LAP/LIP ratio [22,25]. Moreover, stimulation of chicken macrophage
HD11 cells with PMA as well as upregulation of cAMP by incubation
with the adenylyl cyclase activating component forskolin or phosphodi-
esterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), respectively,
increased stability and level of C/EBPβmRNA [44]. Consequently, PKA-
as well as PKC-dependent intracellular signaling pathways appear to
positively regulate C/EBPβ expression [74]. Interestingly, in vitro differ-
entiated (via cell culture for up to 11 days) primary human monocytes
exhibit constant C/EBPβmRNA levels [25].
Using all-trans-retinoic acid (ATRA) or a combination of vitamin D3
(Vit-D3) and transforming growth factor β (TGF-β), U937 cells show
both enhanced expression of C/EBPβ protein and enhanced binding ac-
tivity at C/EBPβ target gene promoters including increased activation of
a C/EBPβ target gene promoter-dependent reporter construct [75,76]. In-
terestingly, following ATRA stimulation, the increase in C/EBPβ was
shown to be inﬂuenced by the availability of the N-Myc downstream-
regulated gene 1 (NDRG1) protein [77]. In ATRA-treated human acute
promyelocytic leukemia NB4 cells, C/EBPβmRNA and (LAP*-/LAP-) pro-
tein expression as well as C/EBPβ DNA binding activity were induced
while C/EBPβmRNA half-life was unaffected [41]. In this case, activation
of the C/EBPβ promoter appears to depend on a positive regulation by
promyelocytic leukemia-retinoic acid receptor α (PML-RARA) [41].
Moreover, the inﬂuence of ATRA on C/EBPβ expression is signiﬁcantly
enhanced in NB4 cells when combined with dehydroepiandrosterone
(DHEA) [78]. Synthetic retinoids which speciﬁcally bind to retinoic acid
receptors α and β, like tamibarotene (tami) and the tamibarotene
dimethylaminoethyl ester A112, are also able to induce C/EBPβ protein
expression in a dose-dependent manner as shown in NB4 cells [79]. In
HL60 cells, it could be shown that the deltanoid 1,25-dihydroxyvitamin
D3 (1,25(OH2)D3) enhances C/EBPβmRNA and protein levels via the ac-
tivation of Raf,mitogen-activated ERK kinase (MEK)/extracellular signal-
regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), respectively
[80–82]. These processes are accompanied by an upregulation of the vi-
tamin D receptor (VDR) as well as the Ras/mitogen-activated protein ki-
nase (MAPK) pathway activating scaffold protein kinase suppressor of
Ras (KSR-1) which presumably ampliﬁes Raf-dependent signal intensity
even in the presence of low deltanoid concentrations [81]. In this con-
text, p38 MAPK appears to repress C/EBPβ mRNA and protein expres-
sion, since both are induced following p38 inhibition [80]. Recent
ﬁndings demonstrate that the treatment of HL60 cellswith the pentacyc-
lic triterpenoid compound ursolic acid (UA) also induces C/EBPβmRNA
and protein expression by activating the ERK pathway [83].
3.2. Proliferation-inducing agents
Analyses in v-Myb and epidermal growth factor receptor (EGFR/
HER1)-transduced chicken myeloblasts showed that the stimulation
Fig. 1. Activators and modulators of the C/EBPβ system. (A, B) Depicted are conditions or molecules inducing a change in the expression of C/EBPβ-LAP*/LAP or LIP proteins (either
in whole cell or cytosolic/nuclear extracts). In addition, associated signaling pathways are shown. (C) Conditions/molecules and signaling pathways are shown which activate or
inhibit the C/EBPβ system (mRNA, phosphorylation, DNA binding activity, and transactivation activity). Modulators which are mentioned in A or B are not enlisted. Further details
are described in Section 3. For abbreviations see text.
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monocyte chemotaxis and macrophage proliferation [84] – enhanced
nuclear translocation of C/EBPβ protein [20]. An increased nuclearlocalization was also observed in chicken macrophages following
transduction with the leukemia virus MH2 which contains the v-mil
(i.e. Raf) oncogene [20]. Murine 32D haematopoietic cells stably
Fig. 1 (continued).
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receptor-3 (FLT3) and stimulated with its ligand FLT3L are character-
ized by elevated C/EBPβ-LIP protein expression accompanied by a de-
creased LAP/LIP ratio [21]. Both effects are also visible in cells
possessing a constitutively activating FLT3 mutation, i.e. FLT3 includ-
ing an internal tandem duplication (ITD) (human AML cell lines MV4-
11, MOLM-13, and PL-21 as well as murine FLT3-ITD-positive 32D
cells). Despite elevated protein levels in ITD-positive cells, unstimu-
lated FLT3-WT- and FLT3-ITD-positive cells exhibit comparable C/
EBPβ mRNA levels [21]. Interestingly, FLT3-ITD-positive and FL-
stimulated FLT3-WT cells initiate different signaling cascades
(mTOR-dependent vs. p90 ribosomal S6 kinase (RSK)-dependent)
[21].
3.3. Cytokines and inﬂammatory substances
The stimulation with IL-6 strongly induces C/EBPβ mRNA expres-
sion in murine M1 myeloid leukemia cells [62,73] and an IL-6-driven
increased binding to and activation of the myeloid differentiation fac-
tor 2 (MD-2) promoter by C/EBPβwas observed in human THP-1 cells
[70]. Analyses performed in murine J774.2 macrophage-like cells
revealed that tumor necrosis factor (TNF), IL-1, and interferon γ
(IFN-γ) induced C/EBPβ mRNA and protein expression as well as C/
EBPβ DNA binding activity [85]. In the murine macrophage-like cell
line RAW 264.7, it could be shown that the IFN-γ-dependent effects
on expression and activation of C/EBPβ protein are mediated via acti-
vation of mitogen-activated protein kinase kinase 1 (MKK1) and ERK
[86]. In human U937 cells, TGF-β stimulation as well as co-cultivation
with TGF-β producing mesenchymal stem cells results in a moderate
induction of both C/EBPβ mRNA and LAP (but not LIP) [87]. This re-
sponse appears to be mediated by TGF-β-dependent protein kinase
B (PKB)/Akt activation. Following phorbol ester-induced differentia-
tion of HL60 cells to macrophages, these cells strongly activate the
C/EBPβ promoter in response to anti-inﬂammatory IL-10, presumably
via STAT3 recruitment, resulting in a massive LIP induction while LAP
is only slightly increased [88]. Conversely, treatment of THP-1 cells
with vascular endothelial growth factor (VEGF) differentially affects
the C/EBPβ isoforms by negatively regulating the concentration ofC/EBPβ-LIP thus increasing the LAP/LIP ratio [89]. In primary human
monocytes as well as in the human AML cell line Mono-Mac 1, activa-
tion of the prostaglandin receptors E-prostanoid 2 (EP2) and 4 (EP4)
following stimulation with prostaglandin E2 (PGE2) yields elevated
levels of cAMP and the subsequent activation of PKA and the p38
MAPK pathway resulting in nuclear translocation and enhanced bind-
ing of C/EBPβ to its recognition sequence [90]. Recently, it has been
shown that C/EBPβ mRNA and protein are induced, C/EBPβ DNA
binding activity is enhanced, and C/EBPβ-dependent gene expression
is increased in RAW264.7 cells treated with IgG immune complexes
(IgG-IC) [91]. Mechanistically, this effect is presumably mediated via
Fcγ receptors, includes the kinases ERK1/2 and p38 MAPK, and is fur-
ther enhanced in the presence of the complement component 5a
(C5a). Increased C/EBPβmRNA and protein levels can also be induced
in U937 cells by addition of polyunsaturated fatty acids such as α-
linolenic acid (LA), arachidonic acid (AA), eicosapentaenoic acid
(EPA), and docosahexaenoic acid (DHA) [92].
3.4. Bacterial and other microbial products
An incubation of human peripheral monocytes as well as rat peri-
toneal macrophages with LPS markedly increased the C/EBPβ mRNA
expression [73,93] and in primary chicken macrophages, an induction
of C/EBPβ protein translocation to the nucleus could be demonstrated
[20]. Further analyses in murine J774.2 and chicken HD11 cells
showed an enhanced C/EBPβ gene transcription in response to LPS
accompanied by elevated protein synthesis and DNA binding activity
[44,85] while C/EBPβ mRNA half-life remained unaffected [44].
Equivalent experiments performed with U937 cells suggest a regula-
tory involvement of protein kinase R (PKR) in enhanced C/EBPβ pro-
tein expression, because PKR inhibition markedly reduced LAP*/LAP
levels [94]. However, since the LPS-driven enhancement of C/EBPβ
DNA binding activity is mimicked by application of forskolin and the
calcium ionophore A23187 (especially when combined), cAMP-
dependent PKA and Ca2+-dependent signaling pathways also appear
to be of importance for C/EBPβ regulation [95]. In primary human
blood monocytes, the stimulation with IFN-γ elevated p38-
mediated C/EBPβ phosphorylation and treatment applying a combi-
nation of LPS and IFN-γ increased the DNA binding activity of C/
EBPβ [96]. In addition, the activation of a (C/EBPβ-regulated) 1α-
hydroxylase promoter-dependent reporter construct was increased
in RAW264.7 cells following stimulation with LPS/IFN-γ. Remarkably,
under these conditions C/EBPβ protein expression was not affected.
In RAW 264.7 cells, the same treatment enhanced DNA binding activ-
ity of full length C/EBPβ, an effect which could be inhibited by appli-
cation of α-melanocyte-stimulating hormone (α-MSH) [97].
Murine bone marrow-derived macrophages challenged with IFN-
γ and/or the 19 kDa lipoprotein from M. tuberculosis exhibited in-
creased C/EBPβ mRNA and LAP*, LAP, and LIP levels as well as inten-
siﬁed binding to C/EBPβ-dependent class II transactivator (CIITA)
promoters I and IV [98]. Comparable results were obtained in
RAW264.7 cells treated with irradiated M. tuberculosis and IFN-γ
[99] or exposed to Escherichia coli [100]. The E. coli-dependent effects
were further enhanced by treatment with adenosine [100]. Remark-
ably, Acholeplasma laidlawii-treated THP-1 cells exhibit a differential
regulation of C/EBPβ isoforms since the expression of LIP is strongly
induced while LAP remains constant [101]. In human bone marrow-
derived macrophages, stimulation with immunostimulatory CpG-
DNA resulted in increased C/EBPβ mRNA and protein expression
(LAP*, LAP, and to a lesser extend LIP) in combination with enhanced
DNA binding activity [102]. Treatment of human and murine primary
monocytes andmacrophages as well as RAW 264.7 cells with a dsRNA
mimetic (polyinosinic:polycytidylic acid) leads to PKR, p38, and ERK
activation and results in enhanced binding of C/EBPβ and activation
of C/EBPβ target gene promoter-dependent reporter constructs, re-
spectively [103]. Moreover; in granulocyte macrophage colony-
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phages, LIP expression is markedly increased following HIV infection
[104].
4. Target genes of C/EBPβ inmonocytic cells and resulting functions
Following activation of C/EBPβ and depending on the prevalent
cellular context, the expression of the respective target genes is en-
hanced or repressed. Thus, many general and monocyte/macro-
phage-speciﬁc cell functions are regulated including proliferation
and differentiation (Fig. 2). In addition, C/EBPβ plays a major role in
the orchestration of the immune response, mainly the cellular branch
of innate immunity. We will also focus on the involvement of C/EBPβ
in leukemia, inﬂammation, and bacterial or viral infections.
4.1. Proliferation and differentiation
4.1.1. Proliferation
Proliferation and cell cycle progression appear to be among the cel-
lular key features inﬂuenced by C/EBPβ in (myelo)monocytic cells
[105]. FLT3L induces the small C/EBPβ isoform LIP in hematopoietic
cells stably transfected with the FLT3-WT receptor thus decreasing the
LAP/LIP ratio which is strongly associated with proliferation [21].
Corresponding data from LIP induction-deﬁcient murine embryonic
ﬁbroblasts show a considerable reduction of cell duplication and prolif-
eration marker expression (proliferating cell nuclear antigen and
cyclins A1, A2, B1, E1, and E2) [106]. Interestingly, the complete absence
of C/EBPβ differentially affects proliferation of cells from distinct devel-
opmental stages, inﬂuencing either early developmental stages (i.e. be-
fore spreading in a granulocytic and a monocytic lineage) or further
differentiated cells: in C/EBPβ-deﬁcient bone marrow-derived progeni-
tor cells, the formation of myeloid colonies inmethylcellulose aswell as
the number of generated cells were signiﬁcantly reduced [107]. In these
experiments, a variety of stimulating agents such as granulocyte
colony-stimulating factor (G-CSF), GM-CSF, and IL-3 were applied. In
contrast, in further differentiated cells, a C/EBPβ knock out generates a
proproliferative situation [22,108]. C/EBPβko mice are characterized by
hyperplastic hematopoiesis and hypermyeloproliferation [108] and in
C/EBPβko macrophages, proliferation rates as well as the amount of
cells exhibiting S or G2/M phase markers are markedly enhanced [22].
This is presumablymediated by the larger C/EBPβ isoforms via different
mechanisms: despite normally acting as transactivators, LAP* and LAP
proteins repress the expression of transcription factor c-Myc in mono-
cytic cells [22,83]. Thus, C/EBPβ decreases proproliferative c-Myc target
genes such as cyclin D but increases cell cycle inhibitors like p27 which
are inhibited by c-Myc [22]. Another effect was originally described in
ﬁbroblasts inwhich C/EBPβ associateswith the Rb-E2F protein complex
and contributes to Rb-dependent cell cycle arrest as well as downregu-
lation of E2F target genes [66,67]. Comparable results were obtained in
ATRA-differentiated [80] as well as C/EBPβ-transduced (pre)monocytic
cells in which C/EBPβ interacts with Rb and/or E2F proteins ([22], K.
Brand unpublished observations). Accordingly, predominant expres-
sion of LAP*/LAP tends to arrest the respective cells in the G0/G1 phase
of the cell cycle and results in a reduced proliferative capacity of mono-
cytic cells [22].
4.1.2. Differentiation
4.1.2.1. Induction of differentiation-associated genes and resulting
functions. C/EBPβ-LAP* and -LAP have been shown to be considerably
connected to monocytic differentiation [105]. The differentiation of
(pre)monocytic cells is characterized by signiﬁcant upregulation of
C/EBPβ, especially LAP* and LAP [20,22,25,73,75,80,83]. This is also
reﬂected by an increasing LAP/LIP ratio [22]. Both effects are also ob-
served during differentiation of other cell types like hepatocytes
[61,109] and adipocytes [110,111].Besides the inhibitory effect of the larger C/EBPβ isoforms on (pre)
monocytic proliferation (as described in Section 4.1.1), C/EBPβ is in-
volved in the regulation of the expression of a variety of differentiation-
associated genes including CD14 [75,80,83,87], macrophage-2 antigen
(Mac-2), Fcγ receptor II (FcγRII) [112], monocyte-speciﬁc esterase [80],
1α-hydroxylase [96], and the cytoplasmic proline-rich tyrosine kinase 2
(Pyk2) [113]. The expression of other genes such as MD-2 and chitotrio-
sidase (CHIT1) is also supported by C/EBPβ by acting as a cofactor of tran-
scription factor PU.1 thus mobilizing its entire transcriptional capacity
[25,70]. Similarly, in the transcription of chicken MER1-repeat-
containing imprinted transcript 1 (mim-1) – which was early identiﬁed
as positively inﬂuenced by C/EBPβ [40,114] – LAP* and LAP enhance c-
Myb-dependent transcription by inducing chromatin opening presum-
ably via recruitment of histone acetylating cofactors of the p300/CBP fam-
ily (by LAP* and LAP) and/or the SWI/SNF chromatin remodeling
complex (exclusively by LAP*) [68,115]. The presence of C/EBPβ and
the activation of itsmaturation-associated target genes is attended by re-
ducedproliferation,morphological changes [22,83], and an increasing an-
timicrobial capacity [83]. Although C/EBPβko mice are able to generate
macrophage-like cells, these cells exhibit a reduced functional potential
since their activation in response to activating stimuli (e.g. LPS, bacteria)
is impaired [108,116]. In immortalizedmacrophage-like cell lines derived
from C/EBPβko mice, the induction of differentiation/activation markers
[112] as well as the development of a typical macrophage morphology
is impaired [22]. Altogether, C/EBPβ-LAP* and -LAP appear to be key fac-
tors especially in terminal monocyte-to-macrophage differentiation.
4.1.2.2. Granulopoiesis and osteoclastogenesis. In progenitor cells exhi-
biting early stages, i.e. in cells providing the formation of both granu-
locytes and monocytes, LAP* and LAP are able to promote the
differentiation of the granulocytic lineage [107,117]. Overexpression
of C/EBPβ in murine primary bone marrow cells results in a reduction
of myeloid progenitor cells in combination with enhanced formation
of granulocytes, while LIP overexpression did not affect myeloid pro-
genitor formation [117]. Moreover, in C/EBPβko mice infected with C.
albicans, a reduced amount of emergency granulopoiesis was shown
[107]. In addition, in patients with congenital neutropenia, G-CSF sig-
niﬁcantly increased the expression of C/EBPβ in bone marrow-
derived myeloid cells resulting in emergency granulopoiesis [118].
In contrast, the formation of osteoclasts from myeloid progenitor
cells is enhanced by LIP but inhibited by the larger isoforms which
is presumably based on the regulation of the osteoclastogenesis in-
hibitor MafB [119,120]. Comparable results were obtained in uORF-
deﬁcient mice which are not able to induce LIP expression, but
show increased levels of MafB in combination with impaired osteo-
clastogenesis [106].
4.1.3. Leukemia
The role of C/EBPα for the development of leukemia has been exten-
sively investigated [121,122]. In this chapter, however, we will focus on
C/EBPβwhich is also often directly connected to thedevelopment of dif-
ferent myelomonocytic leukemias [50,123,124]. For instance, C/EBPβ is
dysregulated in a subtype of AML which is characterized by the consti-
tutively activating ITD mutation of the FLT3 receptor [21]. In ITD-
positive AML patients, enhanced LIP concentrations were observed in
comparison to ITD-negative patients. Accordingly, ITD-positive mono-
cytic cell lines (MV4-11, MOLM-13, PL21) exhibit signiﬁcant LIP levels.
LIP is also highly expressed in a variety of other leukemia cell lines,
e.g. murine K562 erythroleukemia cells [125] or the anaplastic large
cell lymphoma cell lines SUDHL-1, Ki-JK, and Karpas 299 [126]. Compa-
rable results were also obtained in additional types of cancer such as
breast cancer [127–130], as well as several carcinoma cell lines (e.g.
human breast cancer cell line MCF7, human cervical carcinoma cell
line HeLa) [126]. The larger C/EBPβ isoforms, however, are generally re-
duced in strongly proliferating cells, e.g. in bone marrow-derived cells
during blast crisis of chronic myeloid leukemia (CML) patients [131].
LIP Proliferation
(e.g. c-myc, cyclin D)
Differentiation
(e.g. CD14, Mac-2, FcγRII)
Inflammation
(e.g. TNF, IL-1 β, IL-6, IL-8, COX-2)
Phagocytosis/antimicrobial activity
(e.g. iNOS, lysozyme, granulysin,
scavenger receptor)
HIV
Osteoclastogenesis
LAP*/LAP
Early stage
Late stage
LAP/LIP
Orchestration of the
immune response
Fig. 2. C/EBPβ-associated functions and target genes in monocytic cells. The monocytic features and functions inﬂuenced either positively or negatively by LAP*/LAP (blue line) or
LIP (red dotted line), respectively, including selected target genes of C/EBPβ are shown. In addition, the shift in the LAP/LIP ratio during monocyte development from early to late
stages is illustrated. For abbreviations see text.
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mixed lineage leukemia (MLL) which additionally harbor a chromo-
somal insertion interrupting CUGBP1, a protein inﬂuencing C/EBPβ
translation, all C/EBPβ isoforms are virtually absent [132]. In contrast,
the upregulation of LAP*/LAP reduces proliferation and induces differ-
entiation of leukemia cells [41], thus suppressing leukemogenesis in
the corresponding mouse model [133]. The induction of LAP*/LAP by
ATRA in NB4 acute promyelocytic leukemia cells results in the differen-
tiation of these less developedmyelomonocytic cells towards a granulo-
cytic cell type [41]. Accordingly, this approach fails in ATRA-resistant
cells in which larger C/EBPβ isoforms could not be induced [41].
The treatment of primary AML cells with deltanoids [81], U937
leukemia cells with Vit-D3 [134] or ATRA [77] or HL60 leukemia cells
with 1,25(OH2)D3 [80] also induced an increase in C/EBPβ protein as
well as the differentiation of these cells into monocytes. Consequently,
treatment with Vit-D3 derivates and/or analogs may represent a
promising alternative therapeutical approach for leukemia patients
who do not respond to a classical chemotherapy via the induction of
C/EBPβ-supported differentiation [135].
4.2. Orchestration of the immune response
4.2.1. Regulation of inﬂammatory genes
Following the implementation of monocytic differentiation, C/EBPβ
is associated with a variety of immunogenic features [28]. One impor-
tant aspect of monocyte-associated immune response is the production
of C/EBPβ-dependent cytokines and their receptors [11,28]. As shown
in C/EBPβko mice as well as different (pre)monocytic cell lines, C/EBPβ
is involved in the regulation of the expression of TNF, IL-1β, IL-6, IL-12
p35, and IL-10 [100,112,136–139] as well as the receptors for macro-
phage colony-stimulating factor (M-CSFR) and IL-13 (IL-13RA1)
[92,139]. This is consistent with early promoter studies in Jurkat cells
for IL-6 and in murine P19 cells for IL-6 and IL-8 [18,140]. However, ex-
periments performed in an alternative knock out model did not yield
impaired TNF, IL-1, IL-6, IL-10, IL-12, macrophage colony-stimulating
factor (M-CSF), and GM-CSF production [116]. The mRNA expression
of G-CSF in peritoneal macrophages, however, was impaired in this
model [116]. In the case of G-CSF, C/EBPβ-LAP appears to be the isoform
with the strongest inﬂuence on gene expression, since murine LAP-
deﬁcientmacrophages showvirtually no LPS-inducedG-CSF production
[141]. The differences among selected knock out models may resultfrom the analysis of different and functionally heterogeneous macro-
phage populations thus generating distinct phenotypes which may
not be representative of all possible populations [112]. It has also been
proposed that depending on the speciﬁc nuclear composition in C/EBP
factors, C/EBPβ gene products might act as repressors either as the re-
sult of a prevalent function of the inhibitory counterpart LIP and/or
because full length C/EBPβ is a weaker transcriptional activator than
other C/EBP proteins [108]. However, in retransduced cells, C/EBPβ-
dependent cytokine expression is (at least in part) recovered suggesting
that impaired gene expression in the respective knock out model in-
deed appears to be effected by the absence of C/EBPβ [112]. IL-12 p40
appears to be negatively regulated by C/EBPβ since the absence of C/
EBPβ results in the induction of this gene [112]. This inhibition was
shown to be predominately mediated by C/EBPβ-LAP, since this protein
is strongly upregulated in LAP-deﬁcient macrophages in response to
LPS/IFN-γ [141]. However, themore prevalent type of gene suppression
is mediated by LIP, the dominant-negative variant of C/EBPβ [11], as
shown for TNF [138], lL-6, and IL-10 [89].
In addition to cytokines, a variety of chemoattractants are positively
or negatively regulated by C/EBPβ. C/EBPβ induces CC-motif chemokine
receptor 7 [90] and upregulates the CXC chemokines IL-8 (as shown in
ﬁbrosarcoma cells [142]) and stromal cell-derived factor 1 (SDF1) [143]
while CC-motif chemokine ligand 5 (CCL5/RANTES) and macrophage
inﬂammatory protein 1β (MIP1β) appear to be downregulated [112].
In contrast toMIP1β, MIP1α and/orMIP2 have been shown to be not es-
sentially [112,116] or even positively regulated by C/EBPβ [91] in differ-
ent C/EBPβko models [108,116,144].
Among further C/EBPβ-dependent proinﬂammatory genes are
cylooxygenase 2 (COX2) as the generator of prostaglandin H2 [145],
the proinﬂammatory Ca2+-binding proteins S100A8 [103] and S100A9
[103,146], CIITA, a transcriptional co-activator of MHC-II genes [98],
and arginase Iwhich contributes to the development of different inﬂam-
matory diseases [93,147]. Moreover, the NF-κB system is also inﬂuenced
by C/EBPβ which enhances NF-κB-mediated signaling by reducing the
level of the NF-κB inhibitor IκBα [30]. In addition, C/EBPβ contributes
to the development of TNF tolerance: following repeated stimulation
ofmonocytic cellswith lowdoses of TNF, the stimulatory capacity of fur-
ther and even higher doses of TNF for C/EBPβ target gene induction (e.g.
IL-8) is inhibited [148]. In this context, C/EBPβ inhibits function and ac-
tivity of NF-κB by impeding NF-κB p65 phosphorylation via direct
protein-protein interaction [29]. This phenomenon is considered as
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paralysis. In C/EBPβko macrophages, a reduced level of the scavenger
receptor was determined [112]. In this context, it should be men-
tioned that it has been suggested that C/EBP proteins are also in-
volved of the pathogenesis of the chronic inﬂammatory process of
atherosclerosis. For example, it has been shown that oxidized low
density lipoprotein induces the scavenger receptor in smooth mus-
cle cells which correlates with activation of C/EBPβ [149]. In addi-
tion, it has been shown that C/EBP protein decoy oligonucleotides
inhibit macrophage-rich vascular lesion formation in hypercholes-
terimic rabbits [150].
4.2.2. Bacterial infections
A signiﬁcant reduction in the synthesis of phagocytosis-related pro-
teins emerged in C/EBPβ-deﬁcientmonocyte/macrophages characterized
by a decreased expression of receptors recognizing pathogen-associated
molecular patterns (PAMPs) and/or supporting phagocytosis, e.g. the
LPS co-receptor CD14 [75,87], FcγRII, Mac-2, and the above mentioned
scavenger receptor [112]. Furthermore, antimicrobial C/EBPβ target
genes such as inducible nitric-oxide synthase (iNOS) [93,112,145,151], ly-
sozyme [44,95], hepcidin [99], and granulysin [101] are reduced when C/
EBPβ is absent or inhibited. Consequently, C/EBPβko mice are character-
ized by enhanced susceptibility to Candida albicans, Listeria monocyto-
genes, and Salmonella typhimurium infections [108,116]. In this model,
an appreciable amount of pathogens escapes from the phagosome to
the cytoplasm [116] reﬂecting a diminished (but not completely omitted)
antimicrobial activity. Tumor cytotoxicity and tumoristatic activity
against mastrocytoma cells were also markedly impeded [116]. The
amount of phagocytosed particles, however, was not affected [112,116]
and intracellular bacterial killing does not appear to depend necessarily
on thepresence of LAP, since LAP-deﬁcientmacrophages showno impair-
ment of this cellular feature [141]. In murine bonemarrow-derivedmac-
rophages, knock out of the A20-binding inhibitor of NF-κB (ABIN1), an
antiinﬂammatory factor within TLR-dependent signaling which restricts
C/EBPβ expression and activity, results in an excessive upregulation of
C/EBPβ and its proinﬂammatory target genes (e.g. G-CSF and S100A8)
in response to CpG-DNA [102]. In the respective mice, this provokes se-
vere inﬂammation, considerable expansion of myeloid cells, and inﬁltra-
tion of leukocytes in liver, lung, and kidney [102].
4.2.3. Viral infections
C/EBPβ also plays an important role in viral infections (for a de-
tailed review see [12]). The inﬂuence of C/EBPβ on viral infections
has been especially studied in human immunodeﬁciency virus (HIV)
and simian immunodeﬁciency virus (SIV) infections. In general, C/
EBPβ-LAP*/LAP appear to enhance long-terminal repeat (LTR)-
dependent transcription and viral replication of several viruses, e.g.
HIV-1 [12], SIV [152], and Karposi's sarcoma-associated herpesvirus
(KSHV) [153]. In particular, LAP* and LAP support the recruitment
of cofactors to the HIV-1 LTR and interact with histone acetyltransfer-
ase complexes thus presumably facilitating HIV-1 chromatin remo-
deling as shown in U937 cells [154,155]. By positively regulating
viral replication, LAP*/LAP support secondary infections but appear
to be dispensable for the initial infection of monocyte/macrophages
since their inhibition by LIP overexpression has no protective effect
on primary infections [155]. In this context, not only C/EBPβ-
supported HIV-infection of premonocytic cell lines (U1 and U937)
but also primary macrophages may be enhanced by adjacent IL-6
and intercellular adhesion molecule 1 (ICAM-1) expressing endothe-
lial cells [156]. In M-CSF-induced macrophages, LAP* (and to a lesser
extent LAP) expression is detectable and following HIV-1 infection, a
large amount of viral particles is produced while C/EBPβ expression
was not affected [104]. In contrast, not only in GM-CSF-induced mac-
rophages LAP*/LAP but also LIP are strongly expressed and the LIP
concentration markedly increases following HIV infection resulting
in the repression of viral protein expression [104]. The inhibitoryeffect of LIP on HIV replication was also observed in PMA-
differentiated macrophages (derived from THP-1 and HL60 cells) in
which IFN-γ- or IL-10-induced LIP expression lead to inhibition of
LTR-dependent viral transcription and replication [88,157]. Compara-
ble results have been obtained in the SIV model [158]. Hence, the pro-
tective effects of LIP may be utilized in anti-HIV therapy: for instance,
it has been shown that murabutide, a muramyl dipeptide derivate,
suppresses HIV replication by inducing LIP expression in macro-
phages derived from PMA-stimulated THP-1 cells [159]. Another
mechanism is mediated by the protein p27sj isolated from Hypericum
perforatum which associates with C/EBPβ proteins as well as the viral
transactivator protein Tat [160]. Since the formed protein complex is
unable to enter the nucleus but accumulates in a perinuclear cyto-
plasmic compartment, HIV transcription and replication are re-
pressed [160,161].
5. Concluding remarks
In conclusion, the C/EBPβ system is involved in regulating the de-
velopment of (myelo)monocytic cells as well as speciﬁc functions of
this cell type. The short C/EBPβ isoform LIP appears to be associated
with proliferation at myelomonocytic progenitor stages, while LAP*
and LAP may favor the formation of the granulocytic lineage at this
stage. At later developmental stages, i.e. differentiation from premo-
nocytic cells to monocytes and further to macrophages, the larger C/
EBPβ isoforms are associated with inhibition of proliferation and the
expression of differentiation-related genes. Therefore, C/EBPβ may
act as a guide in proliferation control, thereby enabling balanced dif-
ferentiation. In addition, C/EBPβ may represent an important control
system for the tightrope walk between physiologic/inﬂammatory
proliferation and malignant proliferation, i.e. in AML. Another impor-
tant function of the C/EBPβ system in monocytic cells is the orchestra-
tion and regulation of processes mainly related to innate immunity.
During monocytic differentiation, and also upon activation by a
variety of physiological and pathophysiological stimuli, C/EBPβ-
dependent genes such as cytokines, chemokines, and phagocytosis-
associated molecules are induced by LAP*/LAP which is itself limited
by LIP. Dysregulation of C/EBPβ may result in the development and/
or progression of severe disease states such as leukemia, sepsis, and
microbial infection. Further studies are required to exactly character-
ize the role of C/EBPβ in monocytic proliferation/differentiation. In
addition, experiments have to be performed to further elucidate the
signaling modules as well as translational and proteolytic mecha-
nisms leading to C/EBPβ expression. Finally, additional analyses are
necessary to better conceive the involvement of the C/EBPβ system
in inﬂammation and malignancy. Understanding the C/EBPβ system
in monocytic cells may enable the development of diagnostic strate-
gies to better explain on one hand the stages of physiologic and
inﬂammatory proliferation and, on the other hand, malignant prolif-
eration. In addition, therapeutic avenues may offer a feasible means
to better control the excessive inﬂammation mediated by leukocytes
as well as to speciﬁcally address distinct signaling modules in leuke-
mia or antiviral therapy.
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